Skip to main content

Table 1 Patient and tumor characteristics of included breast cancer patients undergoing NACT treatment

From: DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival

  5-year survivors, n = 59* 5-year non-survivors, n = 24*
Age, median (IQR)
 Years 51.5 (44.4 to 56.9) 48.1 (43.9 to 56.8)
Tumor stage, n (%)
 IIB 21 (35.6) 7 (29.2)
 IIIA 24 (40.7) 12 (50.0)
 IIIB 11 (18.6) 3 (12.5)
 IV 3 (5.1) 2 (8.3)
Intrinsic subtype, n (%)
 Basal 5 (9.3) 4 (20.0)
 HER2 enriched 11 (20.4) 5 (25.0)
 Luminal A 12 (22.2) 2 (10.0)
 Luminal B 18 (33.3) 4 (20.0)
 Normal-like 8 (14.8) 5 (25.0)
Treatment response, n (%)
 Partial response 41 (69.5) 11 (45.8)
 Stable disease 18 (30.5) 13 (54.2)
Treatment, n (%)
 Epirubicin 25 (42.4) 8 (33.3)
 Paclitaxel 24 (40.7) 6 (25.0)
 EpiTax** 10 (16.9) 10 (41.7)
  1. *Survivors, n = 59 (24 patients with pre- or post-treatment samples, 35 patients with paired samples). Non-survivors, n = 24 (12 patients with pre- or post-treatment samples, 12 patients with paired samples)
  2. **EpiTax: epirubicin followed by paclitaxel or paclitaxel followed by epirubicin